- EQS-Adhoc: Ad hoc: Arkadius Pichota and Lukas Gilgen appointed to Management Board of MorphoSys AG replacing the current CEO and CFO
- EQS-PVR: MorphoSys AG: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution
- EQS-News: MorphoSys AG Reports First Quarter 2024 Financial Results
- EQS-News: MorphoSys To Present New Phase 3 MANIFEST-2 Data on Pelabresib in Myelofibrosis in Oral Presentation at 2024 ASCO Annual Meeting
- EQS-News: MorphoSys’ Management Board and Supervisory Board Recommend Shareholders Accept Public Takeover Offer by Novartis
More ▼
Key statistics
On Thursday, MorphoSys AG (0NDV:LSE) closed at 66.80, -4.09% below its 52-week high of 69.65, set on May 16, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 66.80 |
---|---|
High | 67.80 |
Low | 67.75 |
Bid | -- |
Offer | -- |
Previous close | 66.80 |
Average volume | 30.84k |
---|---|
Shares outstanding | 37.72m |
Free float | 6.55m |
P/E (TTM) | -- |
Market cap | 2.59bn EUR |
EPS (TTM) | -12.54 EUR |
Data delayed at least 20 minutes, as of Jun 06 2024 15:00 BST.
More ▼